#Japan #Tokyo #gastric cancer #Astellas #ASP2138

Astellas Pharma Launches Phase 3 Trial for ASP2138

Astellas Pharma Inc., a leading global life sciences company, recently reached a significant milestone by dosing the first patient in a Phase 3 trial assessing their innovative drug ASP2138. This trial focuses on adults suffering from locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma, specifically that is positive for Claudin 18.2 (CLDN18.2) and negative for HER2. This initiative is aligned with Astellas' commitment to enhancing the landscape of cancer treatment through rigorous research and development.

Importance of ASP2138

ASP2138 is a bispecific antibody that targets both CLDN18.2, a protein found on certain tumor cells, and CD3-positive T cells, which have the capability to kill those cancer cells. By bridging these two targets, ASP2138 is designed to facilitate a closer interaction between the immune system and cancer cells, potentially amplifying the body's anti-tumor response.

Ongoing advancements in oncology have made it clear that there is a pressing need for new treatment options. Patients with advanced stages of gastric and GEJ cancers often experience dismal prognoses, with median progression-free survival rates hovering between six to seven months using current standard treatments. Recognizing these challenges, Astellas aims to deepen the understanding of CLDN18.2 and leverage various scientific strategies to meet patient needs effectively.

Trial Design and Objectives

This Phase 3 trial is randomized, double-blind, and placebo-controlled, a design that is crucial for ensuring the reliability of the results. The study will compare the efficacy and safety of ASP2138 when combined with chemotherapy (either CAPOX or mFOLFOX6) along with pembrolizumab, against a placebo combined with chemotherapy with or without pembrolizumab. The co-primary endpoints for this trial include overall survival and progression-free survival, and the study aims to enroll 570 participants across multiple countries, reflecting Astellas' ambition for a broad impact in cancer treatment.

Dr. Tadaaki Taniguchi, Astellas' Chief Research and Development Officer, emphasized the significance of dosing the first patient in this trial, noting that it marks an important step in their mission to advance treatments targeting the CLDN18.2 protein. This aligns with Astellas' corporate strategic plan, which seeks to initiate at least five Phase 3 or pivotal studies by the fiscal year 2027.

A Commitment to Oncology

Astellas' focus on CLDN18.2 positive cancers represents a wider commitment to advancing cancer research. Claudin 18.2 is identified as a crucial target in gastric cancer due to its continued expression in certain malignancies, making it an attractive focus for new therapeutic approaches. Through the development of differentiated treatment options, Astellas aims to address the urgent medical needs of patients grappling with this challenging disease landscape.

As the trial progresses, Astellas is committed to providing updates, ensuring stakeholders are informed in accordance with regulatory standards and company policies. With this Phase 3 study, Astellas not only hopes to enhance cancer treatment but also to pave the way for innovations that can significantly influence patient lives and outcomes in the field of oncology.

For more information about the clinical trial, interested parties can search for identifier NCT07673887 on ClinicalTrials.gov.

The Future of ASP2138

While ASP2138 is still investigational, the excitement surrounding its potential contributions to gastric cancer treatment continues to grow within the medical and research communities. Astellas maintains a forward-looking stance on the upcoming phases of this trial, keeping patient care and groundbreaking research at the forefront of their endeavors.

Through this ambitious undertaking, Astellas Pharma stands poised to make vital advancements in the fight against gastric cancer and create solutions that respond to the needs of patients who are often left with minimal options. With the initiation of this trial, the hope for more effective treatment options in the realm of advanced gastric cancers appears closer to reality.